Compare Grab Holdings Ltd. (GRAB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

GRAB trades at $2.91, down 7.62% in the past 24 hours, with technical indicators showing bearish momentum. The company demonstrates strong fundamental improvement with revenue growing from $1.4B in 2022 to $3.37B in 2025 and achieving profitability with $268M net income. Recent developments include the $1.49B acquisition of Atome Financial and aggressive share repurchases, while management has shown confidence through significant insider buying.

GRAB presents a compelling turnaround story with accelerating revenue growth and recent profitability. The stock trades at reasonable valuations (P/E 27.09, P/S 3.65) with 92% analyst buy ratings. Key risks include integration challenges from the Atome acquisition and regional regulatory uncertainties in Southeast Asian markets.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.